Week In Review: 2017 Was Record Investment Year For China Life Science; Final Week Adds $669 Million
December 30, 2017 at 16:42 PM EST
Shanghai's SARI will pay $359 million to acquire a 90% interest in Group NMS, a Milan oncology biopharma. SARI is a biopharma investment firm affiliated with the Chinese Academy of Science research organization with the same name.
